30 January 2026

EVE COMPLETES INITIAL PRODUCTION OF LIBBO™

- Manufacture of Libbo™, EVE's oral dissolving film treatment for erectile dysfunction, completed and inventory delivered to national distributor.
- Distribution, quality and fulfilment systems now in place, supporting imminent market entry.
- Enables near-term commencement of prescribing and patient access via telehealth and pharmacy channels.
- The Libbo™ oral dissolving film format is designed as a discreet and convenient alternative to traditional tablet-based therapies, targeting a faster onset of action.
- Advances EVE's men's health portfolio from development into commercial rollout.

EVE Health Group Limited (ASX: EVE, EVE or the **Company)** is pleased to announce the successful completion of the maiden manufacture run of Libbo™ and the delivery of finished product into national distribution. This milestone marks the transition of Libbo™ from development into commercial launch execution.

Distribution and Launch Readiness

Libbo™ inventory has been manufactured in accordance with applicable regulatory and quality requirements and has successfully completed all required quality assurance processes. Finished stock has now been received by EVE's national distribution partner and integrated into its warehousing, inventory management and fulfilment systems.

With manufacturing and distribution in place, EVE has completed the key operational steps required to support near-term market entry. These include logistics coordination, order management, prescribing support and partner onboarding, positioning the Company to commence initial prescribing and patient access in the near term.

Commercial Strategy

Libbo™ is being commercialised through established telehealth prescribing pathways and pharmacy fulfilment partners, leveraging existing authorised prescriber frameworks and national distribution infrastructure. This model is designed to support scalable national access while maintaining appropriate clinical oversight and efficient patient fulfilment.

The Libbo™ oral dissolving film format is designed as a discreet and convenient alternative to traditional tablet-based therapies, targeting a faster onset of action. Developed using established active pharmaceutical ingredients, the format is intended to support patient engagement and adherence and aligns with EVE's strategy of commercialising differentiated pharmaceutical products in large, underserved markets.

The completion of manufacturing and distribution readiness represents a significant advancement in EVE's men's health portfolio and a further step in executing EVE's pharmaceutical commercialisation strategy.

EVE Chief Executive Officer, Damian Wood, said:

"The completion of Libbo's initial manufacturing represents a major milestone in EVE's progression from development to commercial execution. This achievement reflects the strength of our operational capability and the disciplined approach we have taken to building a scalable supply model. With product now with our distribution partner, we are well positioned to move into market and commence patient access through our established prescribing and fulfilment pathways.

This milestone demonstrates our ability to execute on strategy and build a sustainable revenue-generating business for shareholders."

Market Opportunity and Improving Access to Care

Erectile dysfunction is a common condition, affecting approximately one in five adult men[1] and an estimated 40 percent of men over the age of 40[2], with meaningful impacts on quality of life and mental wellbeing. The global erectile dysfunction treatment market is valued at more than USD 5.3 billion[3] and is expected to grow steadily over the coming decade, driven by increasing awareness, reduced stigma and continued innovation in treatment formats. Despite the availability of effective therapies, many men delay or avoid seeking treatment due to stigma, inconvenience or dissatisfaction with traditional tablet-based options.

Libbo™ is designed to address these barriers by offering a discreet and convenient treatment option, with a delivery format intended to support faster onset, delivered through telehealth and pharmacy-supported access pathways. This approach is intended to support patient engagement, adherence and access to evidence-based care in a large and growing treatment market.

Authorised for release by the Board of Directors.

Company enquiries
+61 8 6465 5500
info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The company's lead assets include Dyspro, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

---

[1] Prevalence and Risk Factors for Erectile Dysfunction in the US, *The American Journal of Medicine*, vol — (2006), https://www.amjmed.com/article/S0002-9343(06)00689-9/fulltext
[2] https://www.singlecare.com/blog/news/erectile-dysfunction-statistics/?utm_source=chatgpt.com
[3] Coherent Market Insights - https://www.coherentmarketinsights.com/market-insight/erectile-dysfunction-market-200